-
EP2635268
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2635268
| EP2635268 - PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 10.02.2017 Database last updated on 14.11.2024 | Most recent event Tooltip | 10.02.2017 | Application deemed to be withdrawn | published on 15.03.2017 [2017/11] | Applicant(s) | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | [N/P] |
| Former [2013/37] | For all designated states Boehringer Ingelheim International GmbH Binger Strasse 173 55216 Ingelheim am Rhein / DE | Inventor(s) | 01 /
HAMILTON, Bradford S. Boehringer Ingelheim GmbH Corporate Patents Binger Str. 173 55216 Ingelheim Am Rhein / DE | 02 /
RAUCH, Thomas Boehringer Ingelheim GmbH Corporate Patents Binger Str. 173 55216 Ingelheim Am Rhein / DE | 03 /
TSUTSUMI, Manami c/o VP, IP, Legal Boehringer Ingelheim USA Corp. 900 Ridgebury Road, P.O. Box 368 CT 06877-0368 Ridgefield / US | [2013/37] | Representative(s) | Dieminger, Wilhelm Gotthard Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | [N/P] |
| Former [2013/37] | Dieminger, Wilhelm Gotthard Boehringer Ingelheim GmbH Corporate Patents Binger Strasse 173 55216 Ingelheim am Rhein / DE | Application number, filing date | 11776777.2 | 28.10.2011 | WO2011EP68938 | Priority number, date | US20100409241P | 02.11.2010 Original published format: US 409241 P | [2013/37] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2012059416 | Date: | 10.05.2012 | Language: | EN | [2012/19] | Type: | A1 Application with search report | No.: | EP2635268 | Date: | 11.09.2013 | Language: | EN | The application published by WIPO in one of the EPO official languages on 10.05.2012 takes the place of the publication of the European patent application. | [2013/37] | Search report(s) | International search report - published on: | EP | 10.05.2012 | Classification | IPC: | A61K31/155, A61K31/422, A61K31/427, A61K31/522, A61K31/7048, A61K45/06, A61P3/00, A61P3/10, A61P9/10, A61P27/06 | [2013/37] | CPC: |
A61K31/5355 (EP,US);
A61K31/535 (KR);
A61K31/155 (EP,US);
A61K31/422 (EP,KR,US);
A61K31/427 (EP,US);
A61K31/4412 (KR);
A61K31/522 (EP,US);
A61K31/7048 (EP,US);
A61K45/06 (EP,US);
A61P13/12 (EP);
A61P25/00 (EP);
A61P27/02 (EP);
A61P27/06 (EP);
A61P3/00 (EP);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/08 (EP);
A61P3/10 (EP);
A61P43/00 (EP);
A61P7/00 (EP);
A61P9/00 (EP);
A61P9/10 (EP)
(-)
| C-Set: |
A61K31/155, A61K2300/00 (EP,US);
A61K31/422, A61K2300/00 (US,EP);
A61K31/427, A61K2300/00 (US,EP);
A61K31/522, A61K2300/00 (US,EP); | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2013/37] | Title | German: | PHARMAZEUTISCHE KOMBINATIONEN ZUR BEHANDLUNG VON STOFFWECHSELERKRANKUNGEN | [2013/37] | English: | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF METABOLIC DISORDERS | [2013/37] | French: | COMBINAISONS PHARMACEUTIQUES DESTINÉES AU TRAITEMENT DE TROUBLES DU MÉTABOLISME | [2013/37] | Entry into regional phase | 03.06.2013 | National basic fee paid | 03.06.2013 | Designation fee(s) paid | 03.06.2013 | Examination fee paid | Examination procedure | 03.06.2013 | Examination requested [2013/37] | 10.12.2013 | Amendment by applicant (claims and/or description) | 21.02.2014 | Despatch of a communication from the examining division (Time limit: M06) | 20.08.2014 | Reply to a communication from the examining division | 13.05.2016 | Communication of intention to grant the patent | 24.09.2016 | Application deemed to be withdrawn, date of legal effect [2017/11] | 28.10.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time [2017/11] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 21.02.2014 | Fees paid | Renewal fee | 31.10.2013 | Renewal fee patent year 03 | 31.10.2014 | Renewal fee patent year 04 | 02.11.2015 | Renewal fee patent year 05 | Penalty fee | Additional fee for renewal fee | 31.10.2016 | 06 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [XD]WO2009134400 (VITAE PHARMACEUTICALS INC [US], et al) [XD] 1-5,9-18 * page 1, lines 15-18 * * page 143; example 148 * * page 170; example 75 * * page 213, line 2 - page 214, line 18 * * page 215, line 3 - page 216, line 2 * * claims 21, 26, 30 *; | [XD]WO2010011314 (BOEHRINGER INGELHEIM INT [DE], et al) [XD] 1-5,9-18 * page 1, lines 18-20 * * page 143; example 48 * * page 168; example 75 * * page 223, line 2 - page 224, line 8 * * page 225, line 3 - page 226, line 3 * * claims 20,21 *; | [X] - ROSENSTOCK JULIO ET AL, "The 11-beta-hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy.", DIABETES CARE JUL 2010 LNKD- PUBMED:20413513, (201007), vol. 33, no. 7, ISSN 1935-5548, pages 1516 - 1522, XP002664645 [X] 1-5,9-18 * the whole document * DOI: http://dx.doi.org/10.2337/dc09-2315 | [Y] - HARNO E ET AL, "Will treating diabetes with 11beta-HSD1 inhibitors affect the HPA axis?", TRENDS IN ENDOCRINOLOGY AND METABOLISM, ELSEVIER SCIENCE PUBLISHING, NEW YORK, NY, US, vol. 21, no. 10, ISSN 1043-2760, (20101001), pages 619 - 627, (20100630), XP027353786 [Y] 1-10,12-18 * the whole document * | [Y] - TADAYYON M ET AL, "INSULIN SENSITISATION IN THE TREATMENT OF TYPE 2 DIABETES", EXPERT OPINION ON INVESTIGATIONAL DRUGS, ASHLEY PUBLICATIONS LTD., LONDON, GB, (20030301), vol. 12, no. 3, doi:10.1517/13543784.12.3.307, ISSN 1354-3784, pages 307 - 324, XP008048351 [Y] 1-10,12-18 * the whole document * DOI: http://dx.doi.org/10.1517/13543784.12.3.307 | by applicant | WO2005092877 | WO2006064033 | WO2006117360 | WO2006117359 | WO2006120208 | WO2007031548 | WO2007093610 | WO2008020011 | WO2008055870 | WO2009134400 | WO2010011314 | - FORD ES ET AL., JAMA., (2002), vol. 287, pages 356 - 9 | - KATSUKI A ET AL., DIABETES CARE, (2001), vol. 24, pages 362 - 5 | - MATTHEWS ET AL., DIABETOLOGIA, (1985), vol. 28, pages 412 - 19 | - FORST ET AL., DIABETES, (2003), vol. 52, no. 1, page A459 | - GALVIN P ET AL., DIABET MED, (1992), vol. 9, pages 921 - 8 | - STUMVOLL ET AL., EUR J CLIN INVEST, (2001), vol. 31, pages 380 - 81 | - J. B. MEIGS ET AL., DIABETES, (2003), vol. 52, pages 1475 - 1484 | - "American Diabetes Association and the National Institute of Diabetes and Digestive and Kidney Diseases", DIABETES CARE, (2002), vol. 25, pages 742 - 749 | - LAAKSONEN DE ET AL., AM J EPIDEMIOL, (2002), vol. 156, pages 1070 - 7 | - "Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III", JAMA: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, (2001), vol. 285, pages 2486 - 2497 | - LAAKSONEN DE ET AL., AM J EPIDEMIOL., (2002), vol. 156, pages 1070 - 7 |